New trial aims to tame brain metastases with smart radiation timing
NCT ID NCT06649058
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 43 times
Summary
This phase 2 trial tests whether adding focused radiation (stereotactic radiosurgery) after initial drug therapy can better control brain metastases that have spread from other cancers. About 316 adults with low-risk brain metastases will receive standard cancer drugs first, then either radiation to all non-responding spots or only to growing ones. The goal is to improve disease control and understand the best timing for radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
stereotactic radiosurgery (focused radiation) and systemic therapy (standard cancer drugs)
What this could lead to
If successful, this could show that adding focused radiation after initial drug therapy helps control brain metastases better, potentially delaying disease progression.
What could go wrong
This is a mid-stage trial with 316 participants, so results are not yet proven. The benefit may be small or not apply to all patients, and radiation carries risks like brain swelling or damage.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.